Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Caterina Alati et al.|The Lancet Haematology|2017Cited by 163
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther Natalie Olíva, Maria Antonietta Aloe Spiriti, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 30
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studyEsther Natalie Olíva, Roberto Latagliata, Maria Cuzzola et al.|Annals of Hematology|2012Cited by 27
Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther Natalie Olíva, Roberto Latagliata, Michael Lauseker et al.|Cancer Medicine|2015Cited by 23
Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)Esther Natalie Olíva, Francesco Nobile, Valeria Santini et al.|Blood|2012Cited by 18